**Multiple Myeloma in Depth: Answering questions on the management of MM patients**

**Hotel International Prague, Czech Republic**

**10–11 October 2019**

**Faculty: Prof Michel Delforge, Belgium; Prof Xavier Leleu, France; Dr Faith Davies, USA; Dr Roman Hàjek, Czech Republic**

**DRAFT AGENDA – DAY 1**

|  |  |  |
| --- | --- | --- |
| **TIME** | **ITEM** | **SPEAKER** |
| **12:45–13:15** | **WELCOME AND INTRODUCTION**  **NAVIGATING THE MM TREATMENT LANDSCAPE** | **M Delforge**  **R Hajek** |
| 30min plenary presentation and Q&A | * Welcoming of delegates and overview of faculty and key goals of the meeting   Introduction session:   * MM mode of disease and importance of targeting the immune microenvironment * Evolving treatment landscape:   + from duplets to triplets   + Incorporation of new treatment options in guidelines     - Evolving ESMO guidelines (2013 and 2017)     - New combination therapies (approved after publication of ESMO guidelines) | Plenary |
| **13:15–14:15** | **SESSION 1: CONSIDERATIONS FOR THE TREATMENT OF NDMM PATIENTS** | **M Delforge** |
| 15min plenary presentation and Q&A | * Considerations, challenges and current management of NDMM patients * Discuss the treatment objectives for different NDMM patients * Remind the attendees of the key factors and challenges associated with treatment decisions for NDMM patients   + Disease-, patient- and treatment-related | Plenary |
| 45min workshop: Current practice in the management of NDMM | Objectives   * Review and discuss current management strategies * Reflect on key selection criteria for treatment decisions   Format   * Each delegate table works as a group using a workmat   How does it work?   * Each group is provided a workmat with a set of questions * The groups fill in the profile with patient characteristics, using ‘typical’ patients, one eligible and one non-eligible for transplant * They identify key patient characteristics that affect treatment strategy * They discuss how they would treat such patients using currently available options and note this management strategy * They discuss the questions provided as a group * Faculty will choose two groups to present for wider group discussion * Faculty close – focus on key patient characteristics and current management strategies, with summary of key learnings from session | All faculty |
| **14:15–15:30** | **SESSION 2: CURRENT TREATMENT OPTIONS FOR NSCT NDMM PATIENTS** | **X Leleu** |
| 50min plenary presentation  + 25min Q&A | * Overview of guidelines and recommendations for the treatment of NSCT NDMM patients * The rationale for investigating RVd in NSCT NDMM * Presentation of the SWOG S0777 trial clinical data * Discuss how the SWOG S0777 clinical data translate into the treatment of patients in clinical practice using a patient case * The rationale for investigating Rd in NSCT NDMM * Presentation of MM-020 trial clinical data   + Efficacy and safety of ITT population   + Including selected key subgroup analysis data * Discuss how the MM-020 clinical data translate into the treatment of patients in clinical practice using a patient case | Plenary |
| **15:30–16:00** | **COFFEE BREAK** |  |
| **16:00–18:00** | **BREAKOUT SESSION 1: MANAGEMENT OF CONTINUOUS THERAPY IN NDMM** | **All faculty** |
| 60min | Topic   * Treatment selection – how to select and adapt treatment according to patient and disease characteristics   Format   * Breakouts in three groups * Relevant data and guidelines presentation * Including discussion of selecting treatments (doublets vs triplets) and adapting treatment doses and schedules * 2–3 case discussions | Breakouts |
| 60min | Topic   * Keeping patients on treatment – from prophylaxis to AE management   *Same format as above*   * Including discussion of management of treatment schedules and AEs | Breakouts |
| **19:30–22:00** | **DINNER** | **All** |

**DRAFT AGENDA – DAY 2**

|  |  |  |
| --- | --- | --- |
| **TIME** | **ITEM** | **SPEAKER** |
| **08:15–08:30** | **WELCOME TO DAY 2** | **M Delforge** |
| **08:30–09:00** | **SESSION 3: MAINTENANCE TREATMENT MANAGEMENT AFTER TRANSPLANT** | **F Davies** |
| 20min plenary presentation  + 10min Q&A | * Overview of guidelines and recommendations for the treatment of NDMM patients eligible for transplant * Remind the audience of the rationale and objectives of maintenance treatment * Presentation of data from trials investigating maintenance (CALGB, IFM, GIMEMA, Myeloma XI, Meta-Analysis)   + Efficacy and safety * Discuss how the clinical data translate into the treatment of patients in clinical practice using a patient case | Plenary |
| **09:00–10:00** | **SESSION 4: TREATMENT OF RRMM PATIENTS** | **F Davies** |
| 40min plenary presentation and case discussion  + 20min Q&A | * Briefly review key considerations impacting treatment decision at relapse * Overview of the approved treatment options at first relapse (considering first line treatment)   + PVd as an option for patients who received ≥1 prior line of therapy including lenalidomide     - Review of MM-007 data * Present the different clinical situations at relapse following lenalidomide treatment in frontline (on/off treatment, dose, clinical/biochemical relapse…) and discuss their implications on treatment decision * Review guidelines recommendations | Plenary |
| **10:00–10:30** | **COFFEE BREAK** |  |
| **10:30–12:00** | **BREAKOUT SESSION 2: CASE DISCUSSION** | **All faculty** |
| 90min | *Attendees will be requested to bring some cases for discussions as breakouts*  Topics   * NDMM patients * RRMM patients | Breakouts |
| **12:00–13:00** | **LUNCH BREAK** |  |
| **13:00–14:00** | **SESSION 5: THE PARADIGM OF TREATMENT IN MM: NOW AND IN THE FUTURE** | **All faculty** |
| 60min panel discussion and audience Q&A | * Potential topics to include:   + Discussion of SWOG S0777 and MM-007 data   + Future perspectives in the management of patients with MM, e.g.:     - Tailoring treatment     - Incorporation of MRD assessment in clinical practice     - Remaining unmet needs in patients with MM     - Incorporation of diagnostic tools (i.e. PET imaging) | Panel discussion / Q&A |
| **14:00–14:15** | **SUMMARY AND CLOSE** | **M Delforge**  All faculty |